Page 56 - CW E-Magazine (Oct-Nov-2023)

Happenings

Anupam Rasayan inks Additionally, Laurus Labs will es- erty rights for Nidlegy for other terri-
pharma ingredients tablish a GMP facility at the Techno tories and indications other than skin
supply deal with 3xper Park facility of IITK. cancers.
Innoventure The Department of Biological Sci- Novo Nordisk & IIIT

Anupam Rasayan, the Surat based ences and Bioengineering (BSBE) at Bangalore to drive
custom synthesis & speciality chemi- IIT Kanpur has been working on gene industry-academia
cals manufacturer, has signed a Memo- therapy for the last few years and has research opportunities
randum of Understanding (MoU) with developed a few gene therapy assets
3xper Innoventure Ltd, a subsidiary along with technology for novel Adeno Novo Nordisk Global Business
of Tube Investments of India Ltd, for Associated Virus (AAV) vectors. They Services (GBS) and the International
supply of “targeted and identified new have filed IPs around these products Institute of Information Technology,
age pharma molecules”. The identified and a few additional patent applications Bangalore (IIIT Bangalore) have inked
products for APIs will be developed will be filed in due course. a Memorandum of Understanding
under the CRAMS and CDMO models, (MoU) to combine IIIT’s technology
the company added. Sun Pharma inks and digital capabilities with Denmark
agreement for Philogen’s
Speaking about the MoU, Mr. under-development cancer headquartered healthcare firm Novo
Anand Desai, Managing Director of Nordisk’s development and data sci-
Anupam Rasayan, said, “We are elated product ence expertise to explore breakthrough
to embark on this technical collabora- Sun Pharmaceutical Industries and innovations and efficiency gains to bet-
tion which will leverage Anupam’s Swiss-Italian biotech firm, Philogen, ter serve the needs of patients.
strong process optimisation capabilities have entered into a licensing agree-
and allowing us to build upon the exist- ment for commercialising Philogen’s
ing robust pipeline of new age pharma speciality cancer product, Nidlegy
molecules with focus on continuous (Daromun) in Europe, Australia, and
processes. This is a natural extension of New Zealand.
our company’s capabilities built over a
decade in flow chemistry to manufac- Nidlegy is a new immunotherapy
ture niche pharma intermediates for product being developed by Philogen
various key customers on custom man- to treat melanoma and non-melanoma
ufacturing model.” skin cancers.
Under the terms of the MoU, IIIT
Laurus Labs signs Under the terms of the agree- Bangalore, and Novo Nordisk GBS
licensing pact with IIT ment, Sun will have exclusive rights will jointly engage in initiatives in-
Kanpur for gene therapy to commercialise Nidlegy for indica- cluding research, innovation projects,
hackathons, case competitions, guest
assets tions of skin cancers in Europe, Aus-
tralia, and New Zealand. Philogen will lectures, education programs, intern-
Laurus Labs has entered into a complete pivotal clinical trials for the ships, placements, employee develop-
Memorandum of Agreement (MOA) product in Europe, pursue Marketing ment, branding and corporate social
with IIT Kanpur (IITK) to bring novel Authorisation with regulatory authori- responsibility collaborations. The MoU
gene therapy assets to market. ties and manufacture commercial sup- is effective from May 19, 2023, for a
plies, a joint note from the companies period of two years.
As per the pact, Hyderabad-based said.
Laurus Labs will in-licence a few gene Besides fostering knowledge shar-
therapy assets and will provide research Sun Pharma will be responsible for ing between industry and academia, the
grants for advancing these products commercialisation activities, it said, partnership will also provide students
through pre-clinical development. It and two partner companies would at IIIT Bangalore with opportunities to
will also provide funding for the clini- equally share post-commercialisa- gain real-world experiences, develop
cal trials and will launch these products tion economics, the company added. new skills, and build relationships with
in India and emerging markets. Philogen will retain intellectual prop- leading industry professionals.

52 Chemical Weekly October / November 2023